V5 Ultimate
Ultimate
PricingResourcesCompany
English (original)العربيةDeutschΕλληνικάEspañolFrançaisItalianoעברית日本語한국어NederlandsPolskiPortuguêsSvenska
Talk to us Log in Start free trial
Food & Beverage
  • Bakery & Confectionery
  • Food Processing
  • Ingredients & Dry Mixes
  • Sausage & Meat Products
  • Produce Packing
  • Pet Food & Pet Supplements
  • Dairy & Chilled Foods
  • Beverages & Liquid Manufacturing
  • Infant Formula
Pharma & Life Sciences
  • Radiopharmaceuticals
  • Pharmaceutical
  • Medical Devices
  • Veterinary Pharmaceuticals
  • Blood & Tissue
  • Diagnostics & IVD Kits
  • Reference Materials & Standards
  • OTC Topical Creams & Gels
Supplements & Personal Care
  • Dietary Supplements
  • Cosmetics & Personal Care
  • Cannabis & Hemp Manufacturing
  • Fragrances & Perfumery
  • Soaps & Personal Hygiene
  • Botanical Extracts & Essential Oils
Chemicals & Materials
  • Plastics & Resins
  • Agricultural Chemicals
  • Specialty & Industrial Chemicals
  • Printing Inks, Pigments & Construction Chemicals
  • Lubricants & Metalworking Fluids
  • Coatings, Adhesives & Sealants
Other Manufacturing
  • Consumer Products
  • Electronics & Electrical Assembly
  • Textiles & Nonwoven
  • Contract Manufacturing & Co-Packing
  • Packaging & Food-Contact Materials
  • Regulated Warehousing & Distribution
Explore all industries
  • Warehouse & TraceabilityReceive, store, pick and trace
  • Production & PlanningPlan jobs and guide production
  • Quality & LaboratoryTest, investigate and review
  • Documents & TrainingControl procedures and qualifications
  • Equipment & PerformanceMaintain assets and measure losses
  • Orders & IntegrationsConnect customers, suppliers and systems
  • Outputs & InsightsReports, KPIs and label design
Why V5? Product & Features
Why V5?Product & Features
  • Warehouse & TraceabilityReceive, store, pick and trace
  • Production & PlanningPlan jobs and guide production
  • Quality & LaboratoryTest, investigate and review
  • Documents & TrainingControl procedures and qualifications
  • Equipment & PerformanceMaintain assets and measure losses
  • Orders & IntegrationsConnect customers, suppliers and systems
  • Outputs & InsightsReports, KPIs and label design
Explore all industries
    • Bakery & Confectionery
    • Food Processing
    • Ingredients & Dry Mixes
    • Sausage & Meat Products
    • Produce Packing
    • Pet Food & Pet Supplements
    • Dairy & Chilled Foods
    • Beverages & Liquid Manufacturing
    • Infant Formula
    • Radiopharmaceuticals
    • Pharmaceutical
    • Medical Devices
    • Veterinary Pharmaceuticals
    • Blood & Tissue
    • Diagnostics & IVD Kits
    • Reference Materials & Standards
    • OTC Topical Creams & Gels
    • Dietary Supplements
    • Cosmetics & Personal Care
    • Cannabis & Hemp Manufacturing
    • Fragrances & Perfumery
    • Soaps & Personal Hygiene
    • Botanical Extracts & Essential Oils
    • Plastics & Resins
    • Agricultural Chemicals
    • Specialty & Industrial Chemicals
    • Printing Inks, Pigments & Construction Chemicals
    • Lubricants & Metalworking Fluids
    • Coatings, Adhesives & Sealants
    • Consumer Products
    • Electronics & Electrical Assembly
    • Textiles & Nonwoven
    • Contract Manufacturing & Co-Packing
    • Packaging & Food-Contact Materials
    • Regulated Warehousing & Distribution
PricingResourcesCompany
Start free trial Log in Talk to us
HomeGlossaryRadiochemical Purity
Lab · The complete guide

Radiochemical Purity: Definition, Testing and Release Role in Radiopharmaceuticals

In short

An analytical guide to measuring the intended radioactive chemical species, interpreting the result and connecting laboratory evidence to a human release decision.

4,096 words · ~19 min read
Radiopharmacy QC technician in hood, mask, safety glasses, gown and gloves reviewing a radiochromatography trace on a tablet at a shielded workstation
On this page
  1. 01What radiochemical purity measures in a sample
  2. 02Radiochemical, radionuclidic and chemical purity compared
  3. 03How radio-TLC and radio-HPLC produce interpretable results
  4. 04From representative sample to a reviewable RCP result
  5. 05US PET drug specifications, method controls and final release
  6. 06Conditional final release and the unavailable-RCP boundary
  7. 07The evidence behind a reported RCP percentage
  8. 08Worked cases: denominator, decay and independent impurities
  9. 09Instrument handoffs and recoverable record failures
  10. 10Failure modes that can distort an RCP result
  11. 11A practical checklist for implementation and review
On this page · 11 sections
  1. 1What radiochemical purity measures in a sample
  2. 2Radiochemical, radionuclidic and chemical purity compared
  3. 3How radio-TLC and radio-HPLC produce interpretable results
  4. 4From representative sample to a reviewable RCP result
  5. 5US PET drug specifications, method controls and final release
  6. 6Conditional final release and the unavailable-RCP boundary
  7. 7The evidence behind a reported RCP percentage
  8. 8Worked cases: denominator, decay and independent impurities
  9. 9Instrument handoffs and recoverable record failures
  10. 10Failure modes that can distort an RCP result
  11. 11A practical checklist for implementation and review
AI · Explain it for MY operation

How does Radiochemical Purity apply to your shop floor?

Pick your industry and scale — Ask V5 rewrites the definition in your context, gives a worked example, and shows what V5 does on day one.

Your scale

01What radiochemical purity measures in a sample

Radiochemical purity is the fraction of the total activity of a specified radionuclide in a sample that is present in the intended chemical form. Abbreviated RCP, it is commonly reported as a percentage. This is a scientific description of how that radionuclide’s activity is distributed among chemical forms, rather than a statutory definition.

Define A_intended as the activity associated with the intended chemical form and A_total as the total activity of the specified radionuclide in the sample. Then RCP = A_intended / A_total, with the fraction expressed as a percentage for reporting. Both activity quantities use compatible units and a consistent measurement basis, including a common time basis where needed. The denominator includes the specified radionuclide in unintended forms, not just the activity assigned to the desired species.

That sample property is distinct from an estimate calculated from recovered chromatographic signal. A normalized peak or zone percentage represents sample RCP only to the extent that separation, detection, response and recovery support the interpretation. If radioactive material is lost before detection or excluded from integration, the measured denominator may not represent the sample’s total activity. Normalization alone does not resolve that gap.

The intended chemical form is product-specific. Activity associated with a free radionuclide, a degradation product or an unintended labelled species may fall outside that definition. Keeping those assignments explicit is useful during analytical method transfer: the receiving laboratory needs the same interpretation of which species belong in A_intended. Acceptance criteria belong to the product specification discussion; they are not part of the definition of RCP.

02Radiochemical, radionuclidic and chemical purity compared

In radiopharmaceutical analytical practice, these terms describe different properties. The denominator matters: an activity fraction is not a mass fraction, an identity assignment or an activity concentration.

TermQuestion answeredTypical evidenceInterpretation boundary
Radiochemical purityWhat fraction of the assessed radioactivity is in the intended chemical form?Suitable radiochemical separation.Denominator: total activity within the stated radiochemical measurement boundary; radionuclide scope matters.
Radionuclidic purityWhat fraction of sample radioactivity belongs to the intended radionuclide?Radionuclide-characterization measurements.Denominator: total activity from all radionuclides in the sample at the stated reference time.
Chemical purityWhat is the chemical composition, including impurities?Appropriate chemical measurements.Chemical amounts or concentrations, not simply radioactive signal.
Radiochemical identityWhich chemical species carries the radioactive signal?Comparison with suitable reference behaviour.Supports species assignment, not its purity percentage.
Specific activityHow much activity is present per mass of the stated material?Activity measurement and corresponding mass determination.Reported as activity per mass, such as Bq/g; the material basis matters.
Activity concentrationHow much activity is present per volume?Activity measurement and corresponding volume determination.Reported as activity per volume, such as Bq/mL; not a purity fraction.

Radioactive and nonradioactive detector responses answer different questions: radiometric detection tracks radioactive species, while chemical detectors respond to substances according to their detection characteristics. An RCP percentage does not independently establish the other properties above. A high RCP value is therefore neither proof of overall chemical cleanliness nor evidence of complete product acceptability.

03How radio-TLC and radio-HPLC produce interpretable results

In radiopharmaceutical analytical practice, radio-TLC and radio-HPLC separate radioactive components before measuring their distribution. Their usefulness depends on whether the established method distinguishes the intended species from relevant impurities—not simply whether it produces a clean-looking trace.

Radio-TLC: interpret migration regions

A sample is applied to a stationary phase, then developed with a solvent system. Components separate into migration regions according to their behaviour under those conditions. Radioactivity is measured by radiometric scanning or by measuring defined strip regions. The established procedure assigns regions to the intended species and relevant impurities.

The stationary phase, solvent system and integration boundaries are method-specific choices. Co-migration can hide an impurity within the intended-species region; material remaining at the application point is not automatically an impurity. Interpretation follows the demonstrated separation, not a generic strip layout.

Radio-HPLC: interpret separated peaks

Radio-HPLC uses chromatographic separation followed by radiometric detection and peak integration. Additional detector channels, such as ultraviolet detection, can help answer complementary analytical questions, but their signals are not interchangeable with radioactivity measurements. Retention behaviour supports a species assignment within the established method; it does not independently establish universal chemical identity. Co-elution can leave different species represented by a single apparent peak.

Select and check the measurement

Practical selection commonly weighs expected impurity classes, resolution, sample preparation, adsorption, recovery, detector operating range and throughput. Losses before detection can make the measured distribution unrepresentative. Neither technique is universally superior or automatically interchangeable with the other.

Method-specific checks commonly address separation performance, detector response and recovery where relevant. For chromatographic workflows, system suitability testing helps distinguish an interpretable run from an unsuitable one. Controlled integration rules typically define region or peak boundaries, baseline treatment and treatment of unresolved signals. An unsuitable run is distinct from a valid measurement that fails an established product criterion; the latter belongs in out-of-specification handling, discussed later in this guide.

These are analytical-practice considerations. The binding method-performance obligation for US PET drugs under 21 CFR 212.60(c) is set out once in the regulatory map below, which develops that method-control obligation separately from technique selection.

04From representative sample to a reviewable RCP result

A typical RCP workflow starts by identifying the batch or sub-batch and selecting the applicable specification and test procedure. Collection and sample login handoff then connect the sample identity to its production context, rather than leaving an instrument run as an isolated result.

Sampling stage matters because an in-process sample may not represent the finished preparation. Handling, storage conditions and elapsed time between collection and testing also affect interpretation. Chemical degradation or radiolysis can alter chemical forms; adsorption onto contact surfaces can change the composition of the sampled liquid. These effects depend on the product and conditions: they are risks to assess, not inevitable changes. Recording this context helps a reviewer judge what the measurement represents.

Before acquisition, laboratories commonly establish run readiness against the selected procedure, including sample preparation and instrument checks. After acquisition, the analyst calculates the result and assembles the data, calculation and relevant observations into a review package. For US PET drugs under 21 CFR 212, 21 CFR 212.60(a) requires laboratories to have and follow written procedures for conducting each test and documenting its results.

Operationally, keep collected, tested, calculated, reviewed and dispositioned states distinguishable in the batch execution history. A missing analytical result is not the same as a completed result awaiting review; neither status alone communicates a disposition decision. The workflow below summarizes common laboratory practice, not additional legal obligations. Detailed release gates belong to the regulatory map.

Identify batch/sub-batch → Select specification and procedure → Collect and identify sample → Establish run readiness → Acquire data → Calculate result → Assemble review package

From sample to human disposition
  1. 1
    Define the testIdentify the product, specification and applicable method version.
  2. 2
    Identify the sampleConnect sampled material with its batch and sampling stage.
  3. 3
    Check run readinessAssess method-specific suitability and instrument operating conditions.
  4. 4
    Acquire Analytical DataPreserve radiometric traces and their sample associations.
  5. 5
    Calculate the FractionApply controlled assignments, integration and denominator rules.
  6. 6
    Review the evidenceExamine validity, specifications, original data and exceptions.
  7. 7
    Record human dispositionConnect the decision with reviewer identity and evidence.
A typical analytical pathway connects sample identity, measurement, supporting evidence and the final human decision.

05US PET drug specifications, method controls and final release

This map addresses US PET drugs under 21 CFR 212; check the applicable current rules for other jurisdictions and product categories. It connects specifications and method controls to the standard batch-release pathway. Conditional final release is addressed separately.

The binding-control column summarizes regulation, not official guidance. The evidence column suggests practical connections for review; it is not a prescribed record format or an exhaustive list of record obligations.

Jurisdiction and product scopeProvisionBinding controlEvidence to connect with the control
US PET drugs under Part 21221 CFR 212.70(a)Establish product specifications covering identity, strength, quality, purity and, where appropriate, sterility and pyrogens.Product specification linked to its RCP criterion and test procedure.
US PET drugs under Part 21221 CFR 212.70(b): new proceduresBefore implementation in a specification, establish and document accuracy, sensitivity, specificity and reproducibility.Method-performance study and supporting results linked to the procedure version.
US PET drugs under Part 21221 CFR 212.70(b): compendial proceduresFirst verify and document that the established compendial procedure works under actual conditions of use.Verification report identifying local operating conditions.
US PET drugs under Part 21221 CFR 212.60(c)Analytical methods must suit their intended use and be sufficiently sensitive, specific, accurate and reproducible.Intended-use statement connected to method-performance evidence.
US PET drug batches under Part 21221 CFR 212.70(c): batchesBefore final release, conduct an appropriate laboratory determination establishing batch conformance to specifications, except for sterility.Batch-linked results and specification comparison.
US PET drug sub-batches under Part 21221 CFR 212.70(c): sub-batchesBefore final release, conduct the corresponding determination for each sub-batch, except for sterility.Sub-batch identifiers connected to their respective determinations.
US PET drugs under Part 21221 CFR 212.70(d)(2)Review associated laboratory data and documentation demonstrating conformance to specifications, except for sterility.Review record connected to underlying data, calculations and results.
US PET drugs under Part 21221 CFR 212.70(d)(3)A designated qualified individual authorizes final release by dated signature.Authorization record identifying the individual, date and batch.

In analytical practice, radio-TLC and radio-HPLC are method options, not universal prescriptions. A proposed electronic batch record design can connect the evidence above for human review; that design is separate from the binding controls. For US PET drugs under Part 212, final-release authorization remains with the designated qualified individual.

06Conditional final release and the unavailable-RCP boundary

For US PET drugs under 21 CFR 212, 21 CFR 212.70(f)(1) permits conditional final release when analytical equipment malfunction prevents completion of a required finished-product test, subject to its stated conditions. This conditional-release pathway is tied to that equipment-malfunction circumstance and the conditions below, not a general permission to defer testing for US PET drugs under Part 212.

Unavailable RCP testing is explicitly excluded

For US PET drugs under 21 CFR 212, 21 CFR 212.70(f)(2) prohibits conditional final release if the equipment malfunction prevents a radiochemical identity/purity test or determination of the product's specific activity—even when the other conditional-release criteria are met.

Conditions and recovery obligations

  • For US PET drugs under 21 CFR 212, 212.70(f)(1)(i) requires data documenting that preceding consecutive batches made using the same methods demonstrate likely conformance of the conditionally released batch with established specifications.
  • For US PET drugs under 21 CFR 212, 212.70(f)(1)(ii) requires determining that all other acceptance criteria are met.
  • For US PET drugs under 21 CFR 212, 212.70(f)(1)(iii) requires retaining a reserve sample of the conditionally released batch.
  • For US PET drugs under 21 CFR 212, 212.70(f)(1)(iv) requires prompt correction of the analytical equipment malfunction, completion of the omitted test using the reserve sample after correction, and documentation of reasonable efforts to prevent recurrence.
  • For US PET drugs under 21 CFR 212, 212.70(f)(1)(v) requires immediate notification of the receiving facility if reserve-sample testing produces an out-of-specification result.
  • For US PET drugs under 21 CFR 212, 212.70(f)(1)(vi) requires documenting all conditional-final-release actions, including the release justification, followup actions, completed testing results, notifications and corrective actions to prevent recurrence of the equipment malfunction.

The next batch remains blocked

For US PET drugs under 21 CFR 212, 21 CFR 212.70(f)(3) prohibits release of another batch of the PET drug product until the analytical equipment problem is corrected and the omitted finished-product test is completed. For US PET drugs under Part 212, equipment repair alone therefore does not satisfy this next-batch release restriction; completion of the omitted test is also necessary.

07The evidence behind a reported RCP percentage

For US PET drugs under 21 CFR 212, 21 CFR 212.60(g)(3) lists a complete record of test data, including the date and time of testing, within laboratory test records. For US PET drugs under the same provision, instrument graphs, charts and spectra are included and identified to the specific tested component, in-process material or drug product and lot.

A practical implementation can connect these records through the suggested data model below. These names are proposed record structures and fields, not prescribed regulatory terminology or capabilities of a particular software product.

ProductSpecification → BatchSample → AnalyticalRun → RCPResult → ReviewDisposition

  • ProductSpecification: identify the applicable specification version; link the result to that version rather than a subsequently revised specification.
  • BatchSample: connect sample identity to the tested batch and product.
  • AnalyticalRun: retain the method version, acquisition date and time, original raw-data location and signal units.
  • RCPResult: retain the numerator, denominator, integration version and result status, linked to the originating run.
  • ReviewDisposition: connect the reviewed result version to the human decision and its review history.

Together, these links make the percentage reconstructable: a reviewer can trace which signals were counted, how they were processed and which specification framed the decision. This is a practical application of data integrity by design.

Keep original acquisition distinct from later processing. Re-integration should create a traceable derived result, not silently replace the original signal record. Preserve the processing context alongside any report; the distinction between dynamic and static records helps explain why a displayed percentage alone is insufficient for reconstruction.

Suggested RCP Evidence Relationships

ProductSpecification

Defines the product-specific analytical decision basis.

  • product_id
  • radionuclide
  • intended_species
  • specification_version
  • rcp_criterion

BatchSample

Identifies material and its sampling context.

  • sample_id
  • batch_id
  • sub_batch_id
  • sampling_stage
  • sampled_at

AnalyticalRun

Links execution context with original data.

  • run_id
  • sample_id
  • method_version
  • instrument_id
  • raw_data_uri

RCPResult

Preserves the calculation basis and reported fraction.

  • result_id
  • run_id
  • intended_signal
  • total_signal
  • signal_unit
  • rcp_percent

ReviewDisposition

Connects reviewed evidence with the human decision.

  • review_id
  • batch_id
  • reviewed_by
  • reviewed_at
  • decision
  • signature_reference
Proposed records connect the applicable specification, sampled material, analytical run, calculated result and human disposition.

08Worked cases: denominator, decay and independent impurities

Case A — An omitted impurity region

Assume complete recovery, resolved intended and impurity regions, comparable detection efficiency, and background-corrected counts measured on a common basis. Let C_intended and C_impurity denote the respective signals, both in counts. Apply the measurement boundary established above: the estimated fraction is C_intended / (C_intended + C_impurity), then expressed as a percentage.

For positive intended and impurity signals, excluding the impurity region understates the denominator while leaving the numerator unchanged, so the reported result rises. A cleaner-looking integration report is not evidence of a cleaner sample. Review which regions entered the calculation, not just the displayed percentage; the omitted signal remains relevant even if it was excluded from the software's integration window.

Case B — Activity loss without chemical conversion

Assume the intended and impurity species contain the same radionuclide, their chemical proportions remain unchanged, and A_intended and A_total are activities in Bq at a common reference time. Applying the same positive, dimensionless decay factor d to both gives: (d × A_intended) / (d × A_total) = A_intended / A_total.

Lower activity therefore need not mean lower RCP. This cancellation concerns the ratio, not the amount of activity available for use. Keep decay correction and reference times explicit when comparing measurements. If chemical conversion changes the distribution, the unchanged-proportions assumption fails and this calculation no longer establishes unchanged RCP.

Case C — Acceptable RCP, independent chemical concern

Assume the radiometric result meets its established product criterion, but a separate chemical-impurity result needs investigation. For this example, integrated radiometric signals are in counts; integrated UV detector signals are in mAU·s, or milli-absorbance-unit seconds. These are different physical responses, not interchangeable peak-area units.

Do not add the channels' raw areas or compare their magnitudes as though they shared a response scale. As the comparison table above explains, RCP and chemical purity address different attributes. Assess the chemical result using its own method, calibration and applicable criterion before disposition. An acceptable radiometric result does not resolve that concern; if the chemical result is outside specification, use the applicable out-of-specification investigation workflow.

09Instrument handoffs and recoverable record failures

A practical interface design carries run_id, sample_id, batch_id, method_version, units, acquisition time, raw-data reference and result status from the instrument to the laboratory record, then links that evidence to the batch record. This production context tagging helps reviewers reconcile the reported RCP result with its originating run. Treat successful transfer, analytical validity and recorded human disposition as separate states: receipt of a file establishes neither a valid result nor approval.

Incident triage commonly distinguishes failures by where the evidence chain breaks:

  • Analytical equipment malfunction: investigate instrument performance and whether the run produced usable analytical evidence.
  • Missing acquisition data: establish what was captured and whether the original measurement record is recoverable.
  • Failed file transfer: check preserved source files and transport logs; an interface failure does not establish successful test performance.
  • Unavailable review system: restore access to the evidence and disposition workflow without assuming that acquisition also failed.

A proposed recovery procedure preserves source files, controls retransmission, detects duplicates, reconciles identifiers and units, restores review access and documents the incident, applying the acquisition-versus-processing distinction already established in the evidence model above rather than restating it. These data-integrity controls support reconciliation; human review and disposition remain separate steps. For release decisions, refer to the conditional-release boundary above rather than treating an integration workaround as a release pathway.

10Failure modes that can distort an RCP result

The following analytical-practice controls apply the denominator and method boundaries discussed above; they are not universal test prescriptions.

Failure modePossible misleading resultPractical controlEvidence to examine
Co-elution or co-migrationImpurity signal counted as productChallenge separation specificityPeak shoulders, reference separations, complementary-method results
Adsorption or incomplete recoverySelective losses inflate or depress RCPAssess recovery across the analytical pathResidual activity, recovery checks, transfer records
Detector saturation or background effectsClipped peaks or inflated low signals distort proportionsCheck response range and backgroundRaw traces, blanks, count-rate records
Sample mismatchValid result assigned to the wrong batchReconcile sample identity at each handoffVial labels, sequence entries, batch identifiers
Uncontrolled integration changesReported RCP changes without analytical justificationUse controlled integration settings and review changesOriginal traces, processing versions, change history

For US PET drugs under 21 CFR 212, 21 CFR 212.60(d) requires adequate control of the identity, purity and quality of reagents, solutions and supplies used in testing. For US PET drugs under 21 CFR 212, the prepared-solution provision in 21 CFR 212.60(d) requires prepared solutions to be labelled with their identity and expiration date.

As investigation practice, investigate plausible analytical causes and document the basis for reintegration or retesting, building on the acquisition-versus-processing distinction established in the evidence model above. Apply this approach during out-of-specification handling: a later favourable result does not itself explain the earlier observation.

11A practical checklist for implementation and review

Use these practice questions to organize implementation and review, not as a universal compliance test. For legal boundaries, refer to the US PET regulatory map and conditional-release section.

Implementation questions

  • Is the intended radiochemical species defined?
  • Is the applicable specification version identifiable?
  • Does the method address relevant impurity behaviour?
  • Are numerator, denominator, units and integration rules explicit?
  • Are sample and run identifiers connected to the relevant batch record?

Review questions

  • Is the sample representative of the decision being made?
  • Is run validity supported?
  • Can the calculation be reconstructed?
  • Are changes and exceptions visible through the audit trail review workflow?
  • Is the relevant human decision connected to the reviewed evidence?

What if a checklist answer is unclear?

Identify the unresolved question and supporting records for review; use the failure-modes section to focus the investigation.

Where should reviewers start reconstructing a result?

Start with the sample and run identifiers, then follow the evidence model above to the calculation and documented decision.

Frequently asked questions

Q.Can a radiochemical purity result establish radiochemical identity on its own?+

Not from the percentage alone. In analytical practice, RCP expresses the fraction of measured radioactivity assigned to the intended chemical form; identity concerns whether that assignment is correct. A dominant radioactive peak could still be misidentified. Laboratories commonly assess assignment using suitable reference comparisons and demonstrated separation from relevant impurities. The chromatography record should therefore distinguish evidence supporting peak identity from the calculation of purity. One analytical procedure may support both conclusions, but the reported RCP value alone does not.

Q.How should a laboratory investigate disagreement between radio-TLC and radio-HPLC?+

As an investigation practice, first establish whether both methods examined comparable samples at comparable times and measured the same impurity population. Compare sample preparation, recovery, detector response, integration rules, and activity retained outside the evaluated regions. Review reagent stability and chromatographic conditions before attributing disagreement to the batch. Laboratories commonly use targeted follow-up testing to distinguish method limitations from genuine sample change. If a result fails its acceptance criterion, use the established out-of-specification investigation rather than selecting the more favorable result.

Q.When might an in-process sample be unsuitable as evidence for a finished-batch decision?+

An in-process sample may not represent the finished material if later operations can change its composition or stability. Examples include purification, formulation, dilution, filtration, or a subsequent hold under different conditions. As a sampling practice, assess the sample’s relationship to the finished batch rather than relying on its label alone. Sample handoff records can clarify collection and handling, while the batch execution history identifies intervening operations. A useful assessment explains why those operations would or would not affect the measured radioactive species.

Q.How should suspected peak co-elution affect interpretation of an RCP result?+

Suspected co-elution weakens the assignment of all activity within a peak to the intended compound. In analytical practice, an apparently clean radioactive peak can contain unresolved radioactive impurities, making its integrated area overstate the intended fraction. Laboratories commonly examine separation selectivity through suitable reference materials, an alternative separation, or a justified change in chromatographic conditions. A stability-indicating method is relevant where degradation products are implicated. Until the assignment is supported, the result should be interpreted as unresolved rather than reassuring merely because it is high.

Q.What should a reviewer examine before accepting a reintegrated chromatogram?+

Building on the acquisition-versus-processing distinction in the evidence model above, review practice starts with the original acquisition, original integration, revised boundaries, and the documented reason for the change. Examine whether baseline placement, excluded regions, peak splitting, or grouping changed the numerator or denominator of the RCP calculation. The audit trail helps establish who changed the processing and when. A defensible review compares both versions against predefined processing rules, not the desired outcome, and any recalculation approval should remain traceable to the underlying data and the scientific justification for accepting the revised interpretation.

Q.Can an unavailable radiochemical purity result be handled like pending sterility testing for a US PET drug?+

No. For US PET drugs, 21 CFR 212.70(c)) excepts sterility—not RCP—from the pre-release determination of conformance to specifications. The conditional-release boundary section above explains the equipment-malfunction trigger under 212.70(f)(1) and the conditions attached to it. Crucially, for US PET drugs, 212.70(f)(2)(2)) prohibits that route when the malfunction prevents a radiochemical identity/purity test. An unavailable RCP result therefore cannot be treated as a routine pending result while the batch is released.

Q.What evidence should a contract testing laboratory return with an RCP value?+

As a contracting practice, specify a review package that connects the reported value to the sample, method version, acquisition, processing, and calculation. Useful contents include sample identifiers, sampling and testing times, chromatograms, integration settings, suitability results, acceptance criteria, analyst identification, and explanations of departures or repeat testing. Consider whether dynamic analytical records, rather than images alone, are needed for meaningful review. Contemporaneous records also help reconstruct sample handling. Agree on access to underlying data before testing begins, not only after a disputed result.

Q.How can a procedure transfer preserve the meaning of the RCP calculation?+

A practical procedure transfer defines which radioactive species belong in the numerator and which measured activity belongs in the denominator. Transfer documentation commonly addresses origin and solvent-front regions, uneluted or unrecovered activity, integration boundaries, background treatment, and any applicable decay correction. Compare representative chromatograms and calculations across laboratories, including difficult separations rather than only clean samples. The aim is to preserve the analytical meaning of the reported fraction despite differences in equipment or software—not merely reproduce a similar final percentage.

Primary sources

  • 21 CFR 212.70 — Controls and acceptance criteria for PET drug products
  • 21 CFR 212.60 — Laboratory controls for PET drugs
Software that covers Radiochemical Purity
V5 Ultimate Radiopharmaceutical Manufacturing
Time-stamped batch record for short production windows, QC results tracked as available or pending, human release review and Part…
Talk to us about Radiochemical Purity

Want to see how Radiochemical Purity could fit into your own records and workflows? Explore the related V5 pages or talk to our team about what applies to your operation.

Start free
Back to glossary
Where this term comes up
RadiopharmaPharmaceutical
Inside V5
  • → eBMR / eDHR — the batch record fills in as the work is done.
Example reports
V5Ultimate

Sample report

Electronic Batch Manufacturing Record (eBMR)

Plan & make

Electronic Batch Manufacturing Record (eBMR)View on screen or print
V5Ultimate

Sample report

Electronic Device History Record (eDHR)

Plan & make

Electronic Device History Record (eDHR)View on screen or print
→ All example reports
Regulatory anchors
  • 21 CFR 212
  • USP <823>
Related terms
  • → Specific Activity
  • → Decay Correction
  • → QP Release

Next Step

Try V5 with your own records, or ask a question first. Ask V5 opens with an editable question; nothing is sent until you choose to.

Start your free trial Browse All Features

Showing the site for the United States. Local spelling, dates and prices are applied automatically; change the language at the top of the page.

V5 Ultimate
Ultimate

Warehouse, quality and manufacturing software for regulated operations.

ProductIndustriesPricingResourcesSecurity & TrustCompanyLegal Centre

© S.G. Systems, LLC